How to predict post TAVR quality of life in “real world” patients

Despite the benefit for most patients, a small number of patients still show poor outcomes after transcatheter aortic valve implantation (TAVR). This work was able to recalibrate a previously developed risk model to predict post TAVR quality of life and provide us with a potential tool to properly estimate the chances of good recovery, or to predict futility and altogether give up the procedure.

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVIThe prior prediction model was developed using data from randomized clinical studies of high-risk TAVR patients. However, this model did not work well with lower risk or unselected ‘real life’ patients. The aim of this study was to optimize this risk model to better predict poor outcomes after TAVR.

 

At one year, of 13351 patients undergoing TAVR in 252 centers in the US from 2011 to 2015, 38.9% had poor outcomes; 20.7% because of death, and 18.2% because of poor or worsening quality of life.


Read also: Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates.


This high rate has fortunately been receding: it has gone from 42% in 2012 to 37.8% in 2015 (p=0.076).

 

The original risk model based on randomized studies did not adjust well to this population of unselected patients.


Read also: Immediate Electrocardiography After TAVI, the Simplest Way to Predict Conduction Disorders.


The study recalibrated model coefficients and retested its capacity to predict poor outcomes, which improved its prediction capacity (both globally and in subgroups) reaching a C index of 0.65, and excellent calibration.

 

Conclusion

A great number of patients still show poor results after TAVR. This recalibrated prediction model at one year is far more accurate and might help us better identify TAVR candidates.

 

Original title: Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population.

Reference: Suzanne V. Arnold et al. Circ Cardiovasc Qual Outcomes. 2018;11:e004693.

 

2018-11-02-CIRCOUTCOMES


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...